MARKET OUTLOOK

Psoriasis Current Treatment: Physician Insights probes the current and future use of topical agents, phototherapy, and systemic therapies in the treatment of mild, moderate, and severe psoriasis in the EU5. It extensively examines the use of approved biologics and Otezla, including patient share, line of therapy, drivers of treatment selection, and barriers to broader uptake. The insights offered are based on primary market research with practicing dermatologists in the EU5.

QUESTIONS ANSWERED

  • Which patients are being prescribed which treatments?
  • What is the sequencing of treatment for psoriasis?
  • What do physicians report as recent and anticipated changes in their treatment practices?
  • What are the dermatologist-reported factors determining current prescribing patterns and recent/anticipated changes?

PRODUCT DESCRIPTION

Current Treatment: Physician Insights provides physician insights on treatment dynamics, prescribing behavior, and drivers of brand use so that clients can create specific messaging around these treatment dynamics in order to more effectively increase or defend their market position.

Markets covered:France, Germany, Italy, Spain, United Kingdom

Primary research: Survey of 253 dermatologists in the EU5 fielded in March 2018.

Key companies: AbbVie, Amgen, Biogen, Celgene, Celltrion, Eli Lilly, Hospira, Janssen, LEO Pharma, Novartis, Sandoz

Key drugs: Benepali, Cosentyx, Enbrel, Erelzi, Flixabi, Humira, Inflectra, Kyntheum, Otezla, Remicade, Remsima, Taltz, Tremfya


Related Reports

Psoriasis - Landscape & Forecast - Disease Landscape & Forecast

The psoriasis therapy market has become increasingly lucrative owing to the growing use of targeted agents. The dominance of the tumor necrosis factor (TNF

View Details

Psoriasis - Current Treatment - Detailed, Expanded Analysis Pediatric Psoriasis - Treatment Algorithms - Claims Data Analysis (US)

Psoriasis is a chronic, inflammatory, autoimmune skin disease that can affect children, adolescents, and adults. Although adult psoriasis and pediatric psoriasis are similar, effective management o...

View Details

Psoriasis | Disease Landscape and Forecast | G7 | 2020

The psoriasis therapy market is becoming increasingly lucrative owing to the growing number of approved biologics. Although TNF-alpha inhibitors continue to dominate the market, their premier posit...

View Details

Psoriasis - Geographic Focus: China - Psoriasis|China In-Depth|China

Psoriasis is an incurable chronic skin condition known to affect more than 8 million people in China. China’s psoriasis market has grown significantly over the last few years owing to the gro...

View Details